2seventy bio, Bristol Myers Squibb Discontinue Enrollment In Phase 3 KarMMa-9 Study
Portfolio Pulse from Benzinga Newsdesk
2seventy bio and Bristol Myers Squibb have decided to discontinue enrollment in the Phase 3 KarMMa-9 study due to improvements in the NDMM treatment landscape and a review of the business case.
September 25, 2024 | 10:03 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
2seventy bio has decided to discontinue enrollment in the Phase 3 KarMMa-9 study, which may impact its future product pipeline and investor sentiment.
The decision to halt enrollment in a Phase 3 study suggests potential setbacks in product development, which could negatively affect investor sentiment and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Bristol Myers Squibb, in collaboration with 2seventy bio, has discontinued enrollment in the Phase 3 KarMMa-9 study, reflecting strategic adjustments in response to the evolving NDMM treatment landscape.
While the discontinuation may reflect strategic realignment, Bristol Myers Squibb's diverse portfolio may mitigate significant short-term impact on its stock price.
CONFIDENCE 85
IMPORTANCE 50
RELEVANCE 60